MARKET

ABCL

ABCL

Abcellera Biologics Inc.
NASDAQ
3.760
+0.100
+2.73%
After Hours: 3.829 +0.069 +1.84% 19:38 04/14 EDT
OPEN
3.780
PREV CLOSE
3.660
HIGH
3.830
LOW
3.695
VOLUME
3.20M
TURNOVER
--
52 WEEK HIGH
6.52
52 WEEK LOW
1.940
MARKET CAP
1.14B
P/E (TTM)
-7.6703
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ABCL last week (0406-0410)?
Weekly Report · 2d ago
How Investors Are Reacting To AbCellera Biologics (ABCL) After New Jones Trading Coverage Initiation
Simply Wall St · 2d ago
A Look At AbCellera Biologics (ABCL) Valuation After New Optimistic Coverage From Jones Trading
Simply Wall St · 4d ago
AbCellera Biologics Initiated at Buy by Jones Trading
Dow Jones · 4d ago
AbCellera Biologics Price Target Announced at $11.00/Share by Jones Trading
Dow Jones · 4d ago
Jones Trading Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $11
Benzinga · 4d ago
AbCellera: De-Risked Antibody Platform With High-Value Menopause Lead and Underappreciated Pipeline Optionality Supporting Buy Rating
TipRanks · 5d ago
AbCellera initiated with a Buy at JonesResearch
TipRanks · 5d ago
More
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Webull offers AbCellera Biologics Inc stock information, including NASDAQ: ABCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABCL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABCL stock methods without spending real money on the virtual paper trading platform.